Head-to-head · Cost-Efficiency Index
NuuVim vs Edessa
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
NuuVim
Cost-first shoppers who want low-cost compounded GLP-1s (injection or oral), flat all-dose pricing.
Visit NuuVimEdessa
A six-month committer, or someone willing to click past the front page to the table with the real monthly rate.
Visit EdessaThe verdict
NuuVim and Edessa tie on the Cost-Efficiency Index at 70/100, so neither wins outright on the numbers. For most shoppers we'd start with NuuVim (ranked #88, a hair above #91) — Cost-first shoppers who want low-cost compounded GLP-1s (injection or oral), flat all-dose pricing. But Edessa is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs NuuVim.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | NuuVim | Edessa |
|---|---|---|
| Cost-Efficiency Index | 70/100 | 70/100 |
| Semaglutide / mo | $79/mo (all doses, 3-mo plan, new patients only, compounded) | $179/mo month-to-month for the injection; $160 on three months and $135 on six |
| Tirzepatide / mo | $133/mo (all doses, 3-mo plan, new patients only, compounded) | $239/mo month-to-month; $219 on three months and $209 on six |
| Semaglutide / yr (modeled) | $948 | $2,148 |
| Tirzepatide / yr (modeled) | $1,596 | $2,868 |
| Coverage | Coverage not published | Not disclosed |
| Oral / sublingual | Yes | Yes |
| Brand-name access | Yes | Compounded only |
| Rank here | #88 | #91 |
NuuVim
70/100Where the value is
- Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
- Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
- LegitScript Certified and HIPAA-compliant
The tradeoffs
- There is no month-to-month plan: every rate is billed as one three-month payment
- The advertised $79 and $133 are introductory rates for customers new to GLP-1s; on renewal they become $133 and $199.67
Edessa
70/100Where the value is
- Each product page carries a plain three-rung table, so the commitment behind every figure is visible
- "Same price, every dose" is printed on each product page
- Names its operating entity and a full street address in Las Vegas, Nevada
The tradeoffs
- The front page leads with "Start for just $135", a six-month prepay on the semaglutide injection
- All three front-page cards quote the six-month rung, so the real monthly rates appear only after a click
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.